Coverage and reimbursement decisions are hardly predictable or consistent within and across US payers. Payers are in the position of determining which drugs to pay for, for whom, and at what level to ...
Peter Salgo, MD: Here [it] comes, I’m afraid to say this, the $64-billion question: cheap drugs, new expensive drugs? What are the coverage criteria for these CGRPR [calcitonin gene-related peptide ...
New for 2015, the CPT codes for vertebroplasty and kyphoplasty were revised to include radiology supervision and interpretation. With the revision the previously existing Local Coverage Determinations ...
Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations—An Exemplar in Brain Tumors Real world data (RWD) were from the Flatiron Health advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results